$IDXG On The Run Again and this time it will be sustained
已更新
Let's recap 
IDXG CC:
1. New York State and AETNA approvals of ThyraMIR®, microRNA assay
2. Talked about the Debt being restructured
3. No more offerings
4. Reduced operating costs
5. Talks of doing business with their BarreGen model
6. Talks of partnering with another bio he didn't discuss.
7. EPS value of $3.25 vs -($12.04) same quarter last year
8. Sales of $3.122 million.
9. Goldman, Rodman and Renshaw, Barclays were on the CC too big boys will be here soon enough count on it.
10. 64% of the S/S is SHORT
11. Raised $14 million in gross equity and restructured over $9.3 million of secured debt
12. Revenue increased 39%
Also most importantly the Patent Approval!!!
IDXG European Patent Decision data.epo.org/publication-server/pdf-document?pn=2772550&ki=B1&cc=EP
ALSO FULL YEAR HIGHLIGHTS READ HERE: ih.advfn.com/p.php?pid=nmona&article=74215692
IDXG CC: 1. New York State and AETNA approvals of ThyraMIR®, microRNA assay
2. Talked about the Debt being restructured
3. No more offerings
4. Reduced operating costs
5. Talks of doing business with their BarreGen model
6. Talks of partnering with another bio he didn't discuss.
7. EPS value of $3.25 vs -($12.04) same quarter last year
8. Sales of $3.122 million.
9. Goldman, Rodman and Renshaw, Barclays were on the CC too big boys will be here soon enough count on it.
10. 64% of the S/S is SHORT
11. Raised $14 million in gross equity and restructured over $9.3 million of secured debt
12. Revenue increased 39%
Also most importantly the Patent Approval!!!
IDXG European Patent Decision data.epo.org/publication-server/pdf-document?pn=2772550&ki=B1&cc=EP ALSO FULL YEAR HIGHLIGHTS READ HERE: ih.advfn.com/p.php?pid=nmona&article=74215692
注释
Alerted this on Twitter earlier in the day. Will post charts in real time next time.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。